**PWE-183** **PRELIMINARY SIGNIFICANT FINDINGS FROM A RANDOMISED CONTROLLED TRIAL OF POSTERIOR TIBIAL NERVE STIMULATION IN SYSTEMIC SCLETEROSIS ASSOCIATED FAECAL INCONTINENCE**

1SK Butt*, 1A Alam, 1A Raeburn, 1J Liwanag, 1VH Ong, 1CP Denton, 1CD Murray, 2N Zarate-Lopez, 1A Emmanuel, 1Gastroenterology, UCL, London, London, UK; 2Rheumatology, Royal Free Hospital, London, London, UK; 3Gastroenterology, Royal Free Hospital, London, London, UK

**Introduction** The gastrointestinal tract is affected in up to 90% of Systemic Sclerosis (SSc) patients with faecal incontinence (FI) being reported in up to 38%. Passive faecal incontinence secondary to internal anal sphincter atrophy is the characteristic finding. We have shown that neuropathic changes are implicated in SSc patients with FI and sacral nerve stimulation has emerged as a potentially beneficial therapy in SSc. However this is expensive, invasive, not widely available and we have shown that medium term efficacy is poor. Posterior tibial nerve stimulation (PTNS) is a potential alternative to modulate the sacral plexus indirectly, with none of these disadvantages. This is the preliminary data on a randomised placebo controlled trial of PTNS versus sham PTNS to determine if nerve modulation is an effective treatment in SSc associated FI.

**Methods** We commenced a prospective randomised single-blind study of SSc patients with FI in February 2013 from a specialist Scleroderma unit. Baseline symptom scoring (bowel diary, Western), manometry and endoanal ultrasound were completed prior to randomization to PTNS or sham. PTNS was administered conventionally, by insertion of an acupuncture needle according to anatomical landmarks, connected to an electrical stimulator. Sham PTNS was administered in identical fashion but the PTNS surface electrode was not connected and instead separate TENS surface electrodes were connected to a TENS unit. Each patient underwent blinded intervention for 30 min periods, once a week for 12 weeks. The primary endpoints were the percentage reduction in faecal incontinence episodes and change in Wexner incontinence scores.

**Results** A total of 13 SSc patients (11 f), mean age 61 (36-72) completed the trial by October 2013. Of these 6 (5 f) underwent PTNS and 7 (6 f) patients underwent sham stimulation. All PTNS patients showed a reduction (5-100%) in the number of FI episodes in comparison to 0 sham patients at 12 weeks (p < 0.01 (CI: -81.49 - 14.34)). This matched an improvement in mean Wexner scores from baseline to treatment end (14.8 to 10.8 vs 13.4 to 13.6, true vs sham respectively, p = 0.03).

**Conclusion** This pilot data is demonstrating significant effects of PTNS in Scleroderma-associated FI. We present this significant initial data but anticipate having at least 25 completed patients by May 2014.

**Disclosure of Interest** None Declared.

**PWE-184** **THE EFFECT OF FIBRE ON CHRONIC CONSTIPATION IN ADULTS: A SYSTEMATIC REVIEW**

1S Christodoulides*, 2E Dimidi, 3K Fragkos, 4PG McLean, 1QA Iziz, 2KW Helen, 1SM Scott. 1Neurogastroenterology Group, Queen Mary University of London, London, UK; 2Diabetes and Nutritional Sciences Division, King’s College London, London, UK; 3Centre for Gastroenterology and Clinical Nutrition, University College London, London, UK; 4Nestlé Research Centre, Lausanne, Switzerland

**Introduction** The effect of fibre on chronic constipation and IBS-C in adults via a systematic review of randomised controlled trials (RCTs). Following Cochrane and PRISMA recommendations, references were identified by searching 5 electronic databases, hand-searching abstracts of 3 annual conferences, as well as scanning reference lists. Two reviewers independently assessed all studies identified, and performed data extraction and risk of bias assessment. Only RCTs reporting administration of fibre (carbohydrate polymers with ≥3 monomers that are not hydrolysed by endogenous enzymes in the small intestine) in adults with either chronic constipation or IBS-C were included.

**Methods** We performed data extraction and risk of bias assessment. Only RCTs reporting administration of fibre (carbohydrate polymers with ≥3 monomers that are not hydrolysed by endogenous enzymes in the small intestine) in adults with either chronic constipation or IBS-C were included.

**Results** Of 916 records identified, only 9 RCTs were eligible (495 patients). Fibre supplements, administered in the form of powder, granules, yoghurt or milk, were: psyllium (n = 3), galacto-oligosaccharides (GOS: n = 2), wheat bran (n = 1), inulin (n = 1), and mixtures of inulin/ resistant maltodextrin (n = 1), and inulin/partially hydrolysed guar gum (n = 1). Outcomes measured included stool frequency (n = 9), stool consistency (n = 6), stool weight (n = 5), faecal microbiota (n = 3) and...
adverse events (n = 3). Four out of 9 RCTs demonstrated a significant increase in stool frequency following fibre consumption compared to placebo. Stool consistency significantly improved following fibre consumption in 2 RCTs, while 4 RCTs failed to show an effect. Three RCTs demonstrated a significant increase in stool weight, but 2 RCTs did not. *Bifidobacteria* significantly increased in 2 out of 3 RCTs (inulin and one GOS intervention). No side effects were observed and no patient withdrew because of adverse events. Attrition bias was high amongst trials, while selection bias and performance bias were unclear due to inadequate reporting. Outcome data will undergo meta-analysis.

**Conclusion** Current guidelines recommend the use of fibre as first-line treatment for constipation. However, this review shows that not all studies support its use in adults. Most studies suffer from small sample sizes and poor design with high risk of bias. The paucity of high quality data highlights the need for further large, methodologically rigorous RCTs.

**Disclosure of Interest** S. Christodoulides Grant/research support from: Nestec Ltd, E. Dimidi Grant/research support from: Nestec Ltd, K. Fragkos: None Declared, P. McLean Employee of: Nestec Ltd, Q. Aziz: None Declared, K. Whelan: None Declared, S. M. Scott: None Declared.

### PWE-185 BELIEFS ABOUT MANAGEMENT OF IRRITABLE BOWEL SYNDROME IN PRIMARY CARE: CROSS-SECTIONAL SURVEY

UN Shivaji*, AC Ford. Leeds Gastroenterology Institute, St. James’s University Hospital, Leeds, UK

10.1136/gutjnl-2014-307263.445

**Introduction** There have been considerable advances in evidence synthesis concerning management of irritable bowel syndrome (IBS) in the last 5 years, with guidelines for its management in primary care published by the National Institute of Health and Care Excellence (NICE). We examined beliefs about IBS management among primary care physicians.

**Methods** This was a cross-sectional web-based questionnaire survey of 275 primary care physicians registered with three clinical commissioning groups in Leeds, UK. We e-mailed a link to a SurveyMonkey questionnaire, containing 18 items, to all eligible primary care physicians. Participants were given 1 month to respond, with a reminder sent out after 2 weeks.

**Results** One-hundred and two (37.1%) primary care physicians responded. Eighty-four (82.4%) of the respondents confirmed that they used clinical symptoms or signs elicited during the history and physical examination to diagnose IBS, with only 10 (9.8%) using the Rome criteria, and 4 (3.9%) the Manning criteria. A further 4 participants stated that they referred to a Gastroenterologist to confirm the diagnosis. Seventy (68.6%) primary care physicians agreed or strongly agreed that IBS was a diagnosis of exclusion, with only 5 (4.9%) strongly disagreeing with this statement. More than 80% checked coeliac serology often or always in suspected IBS. Between 56% and 76% believed soluble fibre, antispasmodics, peppermint oil, and psychological therapies were potentially efficacious therapies (table). The respondents were less convinced that antidepressants or probiotics were effective. Despite perceived efficacy of psychological therapies, 80% stated these were not easily available. Levels of use of soluble fibre, antispasmodics, and peppermint oil were in the range of 40% to >50%. Most primary care physicians obtained up-to-date evidence about IBS management from NICE guidelines.

**Conclusion** Most primary care physicians still believe IBS is a diagnosis of exclusion, and many are reluctant to use antidepressants or probiotics to treat IBS. More research studies addressing diagnosis and treatment of IBS based in primary care are required.

**Disclosure of Interest** None Declared.

### PWE-186 UNDER-UTILISATION OF FECAL CALPROTECTIN TO EXCLUDE IBD IN PATIENTS WITH FUNCTIONAL BOWEL DISORDERS

VI Aedle*, NR Lewis. Nottingham Digestive Diseases Centre, Nottingham University Hospital, Nottingham, UK

10.1136/gutjnl-2014-307263.446

**Introduction** Calprotectin is a protein released by neutrophils in response to the presence of inflammation in the bowel. Based on secondary care data with a cut-off of 50 mcg using ELISA assay it has a sensitivity of 93% and specificity of 94% to exclude inflammatory bowel disease (IBD) from functional bowel disorders. Calprotectin can be measured in a stool sample with this non-invasive test significantly cheaper than endoscopy and associated new patient referral. Faecal calprotectin (FC) has also been shown to correlate with mucosal disease activity and can help to predict response to treatment or relapse in IBD. We report the routine use of FC in gastroenterology practice at our hospital.

**Methods** All FC tests performed between 01/07/12 and 31/12/12 were systematically collected and reason for testing determined. Endoscopic, histological, radiological, laboratory and clinical records were systematically searched to identify tests performed in patients with FC results.

**Results** 294 FC tests were performed during the study period: 203 (69.0%) for assessment of IBD and 91 (31.0%) tests to exclude IBD in patients with suspected functional bowel disorders. Mean age of patients with suspected functional bowel disorders was 45 (SD 16.8) years and 62.6% were female. Of the patients with suspected IBS who had a normal FC value (n = 75), 50.7%